<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836325</url>
  </required_header>
  <id_info>
    <org_study_id>JJJimenez-Rejano, USeville</org_study_id>
    <nct_id>NCT04836325</nct_id>
  </id_info>
  <brief_title>Effect of Transcranial Static Magnetic Field Stimulation in Fibromyalgia Syndrome</brief_title>
  <acronym>TSMFS-FMS</acronym>
  <official_title>Effect of Transcranial Static Magnetic Field Stimulation Over the Primary Motor Cortex in Fibromyalgia Syndrome: A Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Seville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Seville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to know if the transcranial static magnetic field stimulation (tSMS)&#xD;
      reduces the perception of pain in patients with fibromyalgia and its effect on health-related&#xD;
      quality of life. In addition, it will seek to limit the parameters necessary to achieve&#xD;
      efficiency with the technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Various non-invasive brain stimulation techniques have been successfully tested in&#xD;
      fibromyalgia syndrome (FMS). Transcranial static magnetic field stimulation (tSMS) is a new,&#xD;
      portable and inexpensive non invasive brain stimulation (NIBS) technique that has shown&#xD;
      security, biological effects, and therapeutical effects in some pathologies. Some studies&#xD;
      have studied its effect in pain central processing, our aim is to study its effect on FMS.&#xD;
      The safety that tSMS has demonstrated in several clinical trials opens doors to future&#xD;
      clinical trials that will extend its clinical utility.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To investigate the effect of tSMS on pain in patients with FMS, using subjective and&#xD;
      objective assessment measures. Identify dose response to the treatment to limit the&#xD;
      parameters required to achieve effectiveness with the technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Self-reported pain intensity</measure>
    <time_frame>At the start of the study (at baseline, 0 week), after the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week) and 3 months from the last session (16th week)</time_frame>
    <description>Self-reported pain intensity evaluated by the Visual Analogue Scale (VAS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Self-reported quality of life</measure>
    <time_frame>At the start of the study (at baseline, 0 week), after the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week)) and 3 months from the last session (16th week)</time_frame>
    <description>Self-reported quality of life evaluated by the Fibromyalgia Impact Questionnaire (FIQ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Self-reported catastrophizing</measure>
    <time_frame>At the start of the study (at baseline, 0 week), after the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week)) and 3 months from the last session (16th week)</time_frame>
    <description>Self-reported catastrophizing evaluated by the Pain Catastrophizing Scale: 13 items, using the 0 (not at all) to 4 (all the time) scale. A total score is yielded (ranging from 0-52), the worse the result the higher the score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Confidence in the treatment</measure>
    <time_frame>After the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week)) and 3 months from the last session (16th week)</time_frame>
    <description>Confidence in the treatment evaluated by the Patient Global Impression of Change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Global health</measure>
    <time_frame>At the start of the study (at baseline, 0 week), after the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week)) and 3 months from the last session (16th week)</time_frame>
    <description>Self-reported Global health evaluated by the Short form-36 (SF-36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Cognitive impairment</measure>
    <time_frame>At the start of the study (at baseline, 0 week), after the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week)) and 3 months from the last session (16th week)</time_frame>
    <description>Cognitive impairment evaluated by the Multidimensional Inventory of Subjective Cognitive Impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Depression</measure>
    <time_frame>At the start of the study (at baseline, 0 week), after the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week)) and 3 months from the last session (16th week)</time_frame>
    <description>Depression Evaluated by the Hospital Anxiety and Depression Scale: 14 items, 7 for depression and 7 for anxiety. Each item had been answered by the patient on a four-point (0-3) response category so the possible scores ranged from 0 to 21 for anxiety and 0 to 21 for depression, the worse the result the higher the score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Sleep</measure>
    <time_frame>At the start of the study (at baseline, 0 week), after the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week)) and 3 months from the last session (16th week)</time_frame>
    <description>Change from Sleep evaluated by the Medical Outcomes Study Sleep Scale:12 Likert-type items with 6 degrees of response (from 1-always to 6-never). For its interpretation, a gross estimate of the amount of sleep is obtained (item 2) and scores in the different subscales. The direct scores are transformed into a scale from 0 to 100, with no cut-off points; the higher the score, the greater the intensity of the concept evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Physical activity</measure>
    <time_frame>After the 10th session (at the end of the second week), after 20th session (at the end of the fourth week), 1 month from the last session (8th week) and 3 months from the last session (16th week)</time_frame>
    <description>Change from Physical activity evaluated by the International Physical Activity Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Experimental: transcranial static magnetic field stimulation (tSMS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive a treatment of Transcranial Static Magnetic Field Stimulation (tSMS) in the primary motor cortex with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham transcranial static magnetic field stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The placebo group will receive a dummy treatment with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transcranial static magnetic field stimulation (tSMS)</intervention_name>
    <description>The intervention group will receive a treatment of tSMS in the primary motor cortex.</description>
    <arm_group_label>Experimental: transcranial static magnetic field stimulation (tSMS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham transcranial static magnetic field stimulation</intervention_name>
    <description>The placebo group will receive a dummy treatment</description>
    <arm_group_label>Sham transcranial static magnetic field stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Formal diagnosis of fibromyalgia syndrome (FMS).&#xD;
&#xD;
          -  No change in the last 4 weeks on their standard treatment.&#xD;
&#xD;
          -  They must have pain for more than 6 months (at least 4 on the VAS scale).&#xD;
&#xD;
          -  Score on the fibromyalgia impact questionnaire (FIQ) greater than 39.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of concomitant autoimmune or hematologic diseases.&#xD;
&#xD;
          -  Neuropsychiatric disorders.&#xD;
&#xD;
          -  Pacemakers or neurostimulators implants.&#xD;
&#xD;
          -  Substance abuse or other pathologies that can explain chronic pain.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Those who are receiving any other type of physiotherapy treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOSE-JESUS JIMENEZ-REJANO, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Seville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MANUEL DEL-VALLE-GRATACOS, Physiotherapist</last_name>
    <phone>+34620929871</phone>
    <email>manu-valle@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grupo de Investigación Área de Fisioterapia CTS 305 - Universidad de Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JOSE J. JIMENEZ-REJANO, PhD</last_name>
      <phone>+34667309369</phone>
      <email>jjjimenez@us.es</email>
    </contact>
    <investigator>
      <last_name>MANUEL DEL-VALLE-GRATACOS, Physiotherapist</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SAMUEL JIMENEZ-JIMENEZ, Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ANTONIO OLIVIERO, Neurologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Eich W, Bär KJ, Bernateck M, Burgmer M, Dexl C, Petzke F, Sommer C, Winkelmann A, Häuser W. [Definition, classification, clinical diagnosis and prognosis of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles]. Schmerz. 2017 Jun;31(3):231-238. doi: 10.1007/s00482-017-0200-7. Review. German. Erratum in: Schmerz. 2017 Sep 7;:.</citation>
    <PMID>28421273</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolfe F, Walitt B. Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol. 2013 Dec;9(12):751-5. doi: 10.1038/nrrheum.2013.96. Epub 2013 Jul 2. Review.</citation>
    <PMID>23820862</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140.</citation>
    <PMID>20461783</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011 Jun;38(6):1113-22. doi: 10.3899/jrheum.100594. Epub 2011 Feb 1.</citation>
    <PMID>21285161</PMID>
  </results_reference>
  <results_reference>
    <citation>Serra J, Collado A, Solà R, Antonelli F, Torres X, Salgueiro M, Quiles C, Bostock H. Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol. 2014 Feb;75(2):196-208. doi: 10.1002/ana.24065. Epub 2014 Feb 12.</citation>
    <PMID>24243538</PMID>
  </results_reference>
  <results_reference>
    <citation>Gentile E, Ricci K, Delussi M, Brighina F, de Tommaso M. Motor Cortex Function in Fibromyalgia: A Study by Functional Near-Infrared Spectroscopy. Pain Res Treat. 2019 Jan 16;2019:2623161. doi: 10.1155/2019/2623161. eCollection 2019.</citation>
    <PMID>30792923</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Mazzone P, Insola A, Tonali PA, Rothwell JC. The physiological basis of transcranial motor cortex stimulation in conscious humans. Clin Neurophysiol. 2004 Feb;115(2):255-66. Review.</citation>
    <PMID>14744565</PMID>
  </results_reference>
  <results_reference>
    <citation>Groppa S, Oliviero A, Eisen A, Quartarone A, Cohen LG, Mall V, Kaelin-Lang A, Mima T, Rossi S, Thickbroom GW, Rossini PM, Ziemann U, Valls-Solé J, Siebner HR. A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol. 2012 May;123(5):858-82. doi: 10.1016/j.clinph.2012.01.010. Epub 2012 Feb 19. Review.</citation>
    <PMID>22349304</PMID>
  </results_reference>
  <results_reference>
    <citation>Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29. Review.</citation>
    <PMID>27866120</PMID>
  </results_reference>
  <results_reference>
    <citation>Capone F, Dileone M, Profice P, Pilato F, Musumeci G, Minicuci G, Ranieri F, Cadossi R, Setti S, Tonali PA, Di Lazzaro V. Does exposure to extremely low frequency magnetic fields produce functional changes in human brain? J Neural Transm (Vienna). 2009 Mar;116(3):257-65. doi: 10.1007/s00702-009-0184-2. Epub 2009 Feb 3.</citation>
    <PMID>19189041</PMID>
  </results_reference>
  <results_reference>
    <citation>Capone F, Pellegrino G, Motolese F, Rossi M, Musumeci G, Di Lazzaro V. Extremely Low Frequency Magnetic Fields Do Not Affect LTP-Like Plasticity in Healthy Humans. Front Hum Neurosci. 2020 Feb 5;14:14. doi: 10.3389/fnhum.2020.00014. eCollection 2020.</citation>
    <PMID>32116603</PMID>
  </results_reference>
  <results_reference>
    <citation>Oliviero A, Mordillo-Mateos L, Arias P, Panyavin I, Foffani G, Aguilar J. Transcranial static magnetic field stimulation of the human motor cortex. J Physiol. 2011 Oct 15;589(Pt 20):4949-58. doi: 10.1113/jphysiol.2011.211953. Epub 2011 Aug 1.</citation>
    <PMID>21807616</PMID>
  </results_reference>
  <results_reference>
    <citation>Shibata S, Watanabe T, Yukawa Y, Minakuchi M, Shimomura R, Mima T. Effect of transcranial static magnetic stimulation on intracortical excitability in the contralateral primary motor cortex. Neurosci Lett. 2020 Apr 1;723:134871. doi: 10.1016/j.neulet.2020.134871. Epub 2020 Feb 25.</citation>
    <PMID>32109553</PMID>
  </results_reference>
  <results_reference>
    <citation>Oliviero A, Carrasco-López MC, Campolo M, Perez-Borrego YA, Soto-León V, Gonzalez-Rosa JJ, Higuero AM, Strange BA, Abad-Rodriguez J, Foffani G. Safety Study of Transcranial Static Magnetic Field Stimulation (tSMS) of the Human Cortex. Brain Stimul. 2015 May-Jun;8(3):481-5. doi: 10.1016/j.brs.2014.12.002. Epub 2014 Dec 11.</citation>
    <PMID>25595064</PMID>
  </results_reference>
  <results_reference>
    <citation>Dileone M, Mordillo-Mateos L, Oliviero A, Foffani G. Long-lasting effects of transcranial static magnetic field stimulation on motor cortex excitability. Brain Stimul. 2018 Jul - Aug;11(4):676-688. doi: 10.1016/j.brs.2018.02.005. Epub 2018 Feb 7.</citation>
    <PMID>29500043</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirimoto H, Tamaki H, Otsuru N, Yamashiro K, Onishi H, Nojima I, Oliviero A. Transcranial Static Magnetic Field Stimulation over the Primary Motor Cortex Induces Plastic Changes in Cortical Nociceptive Processing. Front Hum Neurosci. 2018 Feb 15;12:63. doi: 10.3389/fnhum.2018.00063. eCollection 2018.</citation>
    <PMID>29497371</PMID>
  </results_reference>
  <results_reference>
    <citation>Knijnik LM, Dussán-Sarria JA, Rozisky JR, Torres IL, Brunoni AR, Fregni F, Caumo W. Repetitive Transcranial Magnetic Stimulation for Fibromyalgia: Systematic Review and Meta-Analysis. Pain Pract. 2016 Mar;16(3):294-304. doi: 10.1111/papr.12276. Epub 2015 Jan 12. Review.</citation>
    <PMID>25581213</PMID>
  </results_reference>
  <results_reference>
    <citation>Lloyd DM, Wittkopf PG, Arendsen LJ, Jones AKP. Is Transcranial Direct Current Stimulation (tDCS) Effective for the Treatment of Pain in Fibromyalgia? A Systematic Review and Meta-Analysis. J Pain. 2020 Nov - Dec;21(11-12):1085-1100. doi: 10.1016/j.jpain.2020.01.003. Epub 2020 Jan 23.</citation>
    <PMID>31982685</PMID>
  </results_reference>
  <results_reference>
    <citation>Paolucci T, Piccinini G, Iosa M, Piermattei C, de Angelis S, Grasso MR, Zangrando F, Saraceni VM. Efficacy of extremely low-frequency magnetic field in fibromyalgia pain: A pilot study. J Rehabil Res Dev. 2016;53(6):1023-1034. doi: 10.1682/JRRD.2015.04.0061.</citation>
    <PMID>28475205</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirimoto H, Tamaki H, Matsumoto T, Sugawara K, Suzuki M, Oyama M, Onishi H. Effect of transcranial static magnetic field stimulation over the sensorimotor cortex on somatosensory evoked potentials in humans. Brain Stimul. 2014 Nov-Dec;7(6):836-40. doi: 10.1016/j.brs.2014.09.016. Epub 2014 Sep 30.</citation>
    <PMID>25444588</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirimoto H, Asao A, Tamaki H, Onishi H. Non-invasive modulation of somatosensory evoked potentials by the application of static magnetic fields over the primary and supplementary motor cortices. Sci Rep. 2016 Oct 4;6:34509. doi: 10.1038/srep34509.</citation>
    <PMID>27698365</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Seville</investigator_affiliation>
    <investigator_full_name>JJ JIMENEZ-REJANO</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>transcranial static magnetic field stimulation</keyword>
  <keyword>fibromyalgia</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

